CN121511297A - 修饰噬菌体 - Google Patents

修饰噬菌体

Info

Publication number
CN121511297A
CN121511297A CN202480044785.4A CN202480044785A CN121511297A CN 121511297 A CN121511297 A CN 121511297A CN 202480044785 A CN202480044785 A CN 202480044785A CN 121511297 A CN121511297 A CN 121511297A
Authority
CN
China
Prior art keywords
bacteriophage
genome
phage
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480044785.4A
Other languages
English (en)
Chinese (zh)
Inventor
松冈秀明
松井稔幸
坂井星辰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arlo Smith Co ltd
Original Assignee
Arlo Smith Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arlo Smith Co ltd filed Critical Arlo Smith Co ltd
Publication of CN121511297A publication Critical patent/CN121511297A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202480044785.4A 2023-07-14 2024-07-12 修饰噬菌体 Pending CN121511297A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023-116013 2023-07-14
JP2023116013 2023-07-14
PCT/JP2024/025265 WO2025018295A1 (ja) 2023-07-14 2024-07-12 改変バクテリオファージ

Publications (1)

Publication Number Publication Date
CN121511297A true CN121511297A (zh) 2026-02-10

Family

ID=94282182

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480044785.4A Pending CN121511297A (zh) 2023-07-14 2024-07-12 修饰噬菌体

Country Status (5)

Country Link
EP (1) EP4745231A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2025018295A1 (cg-RX-API-DMAC7.html)
CN (1) CN121511297A (cg-RX-API-DMAC7.html)
TW (1) TW202517778A (cg-RX-API-DMAC7.html)
WO (1) WO2025018295A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122060690A (zh) * 2026-04-01 2026-05-19 深圳市百泽诺科生物技术有限公司 一种分枝杆菌噬菌体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3358015A1 (en) * 2017-02-03 2018-08-08 Eligo Bioscience Optimized vector for delivery in microbial populations
US11066691B1 (en) * 2018-09-14 2021-07-20 National Technology & Engineering Solutions Of Sandia, Llc Therapeutic phages and methods thereof
CN114981408A (zh) * 2019-11-06 2022-08-30 洛可斯生物科学公司 Crispr cas系统和溶原性模块
WO2021092362A1 (en) 2019-11-07 2021-05-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of specific phages for the treatment of nontuberculous mycobacteria (ntm) infections
JP2023116013A (ja) 2022-02-09 2023-08-22 セイコーエプソン株式会社 測色装置
EP4516898A4 (en) * 2022-04-28 2026-05-06 Arrowsmith Inc BACTERIOPHAGE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122060690A (zh) * 2026-04-01 2026-05-19 深圳市百泽诺科生物技术有限公司 一种分枝杆菌噬菌体及其应用

Also Published As

Publication number Publication date
JPWO2025018295A1 (cg-RX-API-DMAC7.html) 2025-01-23
WO2025018295A1 (ja) 2025-01-23
EP4745231A1 (en) 2026-05-20
TW202517778A (zh) 2025-05-01

Similar Documents

Publication Publication Date Title
US7163818B2 (en) Bacteriophage having multiple host range
US8535939B2 (en) Transfection vector
US6896882B2 (en) Lysin-deficient bacteriophages having reduced immunogenicity
US11590215B2 (en) Process for the production of a DNA vaccine for cancer immunotherapy
JP2011504366A5 (cg-RX-API-DMAC7.html)
EP4032526A1 (en) Bacteriophage for modulating inflammatory bowel disease
Zheng Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy
EP4516898A1 (en) Bacteriophage
Suvorov et al. Construction of the enterococcal strain expressing immunogenic fragment of SARS-CoV-2 virus
WO2025018295A1 (ja) 改変バクテリオファージ
Adamczyk-Popławska et al. The potential for bacteriophages and prophage elements in fighting and preventing the gonorrhea
JP4495143B2 (ja) 生物学的安全性が向上した経口ワクチン接種用凍結乾燥形態のコレラ菌弱毒化株
EP3215174B1 (en) Monocins and methods of use
AU2018217936A1 (en) Rebooting of synthetic bacteriophage genome in L-form bacteria
JP7836794B2 (ja) 遺伝子操作された、生きている細菌及びその構築方法
CA2504331A1 (en) Bacteriophage having modified holin and uses thereof
JP2023528151A (ja) エンテロシンおよびその使用方法
US20240254167A1 (en) Genetically modified clostridium strains expressing recombinant antigens and uses thereof
Kalarus Deletion of prophages in Clostridioides difficile
Lança Studies on the regulation of bacteriocin loci in Streptococcus mitis
Borralho Studies on the regulation of bacterioci loci in Streptococcus mitis
Hossain Molecular Interactions between phage and the catfish pathogen Edwardsiella ictaluri and Comparative Genomics of Epidemic strains of Aeromonas hydrophila
CN121950722A (zh) 一种基于T4gp10样结构域的工程化噬菌体构建平台
Schmitz et al. Identifying phage lytic enzymes: past, present, and future

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination